Published in Cell on August 25, 2011
MYC on the path to cancer. Cell (2012) 8.65
Hypoxia-inducible factors in physiology and medicine. Cell (2012) 8.16
A validated regulatory network for Th17 cell specification. Cell (2012) 4.82
Metabolic regulation of T lymphocytes. Annu Rev Immunol (2013) 3.67
Fueling immunity: insights into metabolism and lymphocyte function. Science (2013) 3.62
The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing. Nat Rev Immunol (2014) 2.82
Regulation and function of mTOR signalling in T cell fate decisions. Nat Rev Immunol (2012) 2.79
Normalization of CD4+ T cell metabolism reverses lupus. Sci Transl Med (2015) 2.70
Th17 cells are long lived and retain a stem cell-like molecular signature. Immunity (2011) 2.64
A role for the NLRP3 inflammasome in metabolic diseases--did Warburg miss inflammation? Nat Immunol (2012) 2.59
The updated biology of hypoxia-inducible factor. EMBO J (2012) 2.49
Metabolic checkpoints in activated T cells. Nat Immunol (2012) 2.47
Transcription factor Foxp3 and its protein partners form a complex regulatory network. Nat Immunol (2012) 2.10
Signaling by the phosphoinositide 3-kinase family in immune cells. Annu Rev Immunol (2013) 2.09
Interferon-γ Drives Treg Fragility to Promote Anti-tumor Immunity. Cell (2017) 2.06
T cell metabolism drives immunity. J Exp Med (2015) 2.06
Stabilization of the transcription factor Foxp3 by the deubiquitinase USP7 increases Treg-cell-suppressive capacity. Immunity (2013) 2.05
Metabolic pathways in T cell fate and function. Trends Immunol (2012) 1.97
Integrating canonical and metabolic signalling programmes in the regulation of T cell responses. Nat Rev Immunol (2014) 1.96
MicroRNA-containing T-regulatory-cell-derived exosomes suppress pathogenic T helper 1 cells. Immunity (2014) 1.95
STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients. J Clin Invest (2013) 1.94
A multiply redundant genetic switch 'locks in' the transcriptional signature of regulatory T cells. Nat Immunol (2012) 1.93
Follicular helper T cells in immunity and systemic autoimmunity. Nat Rev Rheumatol (2012) 1.89
Hypoxia-inducible factors enhance the effector responses of CD8(+) T cells to persistent antigen. Nat Immunol (2013) 1.86
Control of PI(3) kinase in Treg cells maintains homeostasis and lineage stability. Nat Immunol (2015) 1.78
mTOR, metabolism, and the regulation of T-cell differentiation and function. Immunol Rev (2012) 1.74
Molecular regulation of effector and memory T cell differentiation. Nat Immunol (2014) 1.70
Hypoxia-inducible factor-1 alpha-dependent induction of FoxP3 drives regulatory T-cell abundance and function during inflammatory hypoxia of the mucosa. Proc Natl Acad Sci U S A (2012) 1.70
AMPKα1 deficiency amplifies proinflammatory myeloid APC activity and CD40 signaling. J Leukoc Biol (2013) 1.65
The ubiquitin ligase Stub1 negatively modulates regulatory T cell suppressive activity by promoting degradation of the transcription factor Foxp3. Immunity (2013) 1.62
Metabolic programming and PDHK1 control CD4+ T cell subsets and inflammation. J Clin Invest (2014) 1.58
PI3K signalling in B- and T-lymphocytes: new developments and therapeutic advances. Biochem J (2012) 1.56
HIF transcription factors, inflammation, and immunity. Immunity (2014) 1.55
Foxp3 and Toll-like receptor signaling balance Treg cell anabolic metabolism for suppression. Nat Immunol (2016) 1.55
An N-terminal mutation of the Foxp3 transcription factor alleviates arthritis but exacerbates diabetes. Immunity (2012) 1.50
Hypoxia--a key regulator of angiogenesis and inflammation in rheumatoid arthritis. Nat Rev Rheumatol (2012) 1.41
Mitochondria in the regulation of innate and adaptive immunity. Immunity (2015) 1.40
CD5L/AIM Regulates Lipid Biosynthesis and Restrains Th17 Cell Pathogenicity. Cell (2015) 1.38
Oxygen sensing and hypoxia signalling pathways in animals: the implications of physiology for cancer. J Physiol (2013) 1.35
Metabolic reprogramming is required for antibody production that is suppressed in anergic but exaggerated in chronically BAFF-exposed B cells. J Immunol (2014) 1.35
Metabolic control of type 1 regulatory T cell differentiation by AHR and HIF1-α. Nat Med (2015) 1.35
PKM2 regulates the Warburg effect and promotes HMGB1 release in sepsis. Nat Commun (2014) 1.29
The plasticity of human Treg and Th17 cells and its role in autoimmunity. Semin Immunol (2013) 1.29
Cytokines in radiobiological responses: a review. Radiat Res (2012) 1.29
Negative regulation of Hif1a expression and TH17 differentiation by the hypoxia-regulated microRNA miR-210. Nat Immunol (2014) 1.27
Metabolic control of the Treg/Th17 axis. Immunol Rev (2013) 1.26
The Interleukin-2-mTORc1 Kinase Axis Defines the Signaling, Differentiation, and Metabolism of T Helper 1 and Follicular B Helper T Cells. Immunity (2015) 1.20
Mechanisms underlying helper T-cell plasticity: implications for immune-mediated disease. J Allergy Clin Immunol (2013) 1.19
Treg cells, life history, and diversity. Cold Spring Harb Perspect Biol (2012) 1.19
Hypoxia and hypoxia-inducible factors as regulators of T cell development, differentiation, and function. Immunol Res (2013) 1.19
Metabolic reprogramming and metabolic dependency in T cells. Immunol Rev (2012) 1.18
Treg and CTLA-4: two intertwining pathways to immune tolerance. J Autoimmun (2013) 1.18
Targeting hypoxia signalling for the treatment of ischaemic and inflammatory diseases. Nat Rev Drug Discov (2014) 1.17
Itk-mediated integration of T cell receptor and cytokine signaling regulates the balance between Th17 and regulatory T cells. J Exp Med (2014) 1.16
Targeting orphan nuclear receptors for treatment of metabolic diseases and autoimmunity. Chem Biol (2012) 1.16
Functional importance of Dicer protein in the adaptive cellular response to hypoxia. J Biol Chem (2012) 1.15
Harnessing the plasticity of CD4(+) T cells to treat immune-mediated disease. Nat Rev Immunol (2016) 1.15
Regulation and function of innate and adaptive interleukin-17-producing cells. EMBO Rep (2012) 1.14
T cell metabolic fitness in antitumor immunity. Trends Immunol (2015) 1.12
mTOR and metabolic pathways in T cell quiescence and functional activation. Semin Immunol (2013) 1.11
mTOR and lymphocyte metabolism. Curr Opin Immunol (2013) 1.11
Hypoxia-inducible factors in regulation of immune responses in tumour microenvironment. Immunology (2014) 1.10
The role and regulation of human Th17 cells in tumor immunity. Am J Pathol (2012) 1.09
Retracted Natural and inducible TH17 cells are regulated differently by Akt and mTOR pathways. Nat Immunol (2013) 1.09
MicroRNA-21 promotes Th17 differentiation and mediates experimental autoimmune encephalomyelitis. J Clin Invest (2015) 1.09
Mammalian target of rapamycin integrates diverse inputs to guide the outcome of antigen recognition in T cells. J Immunol (2012) 1.08
Intra-amniotic IL-1β induces fetal inflammation in rhesus monkeys and alters the regulatory T cell/IL-17 balance. J Immunol (2013) 1.08
Action of RORs and their ligands in (patho)physiology. Trends Endocrinol Metab (2012) 1.08
Conversion of peripheral blood NK cells to a decidual NK-like phenotype by a cocktail of defined factors. J Immunol (2013) 1.07
Glucose metabolism regulates T cell activation, differentiation, and functions. Front Immunol (2015) 1.07
Activated lymphocytes as a metabolic model for carcinogenesis. Cancer Metab (2013) 1.07
Metabolic control of regulatory T cell development and function. Trends Immunol (2014) 1.06
Helper T-cell identity and evolution of differential transcriptomes and epigenomes. Immunol Rev (2013) 1.05
Shigella: a model of virulence regulation in vivo. Gut Microbes (2012) 1.04
Metformin attenuates experimental autoimmune arthritis through reciprocal regulation of Th17/Treg balance and osteoclastogenesis. Mediators Inflamm (2014) 1.04
Extracellular adenosine-mediated modulation of regulatory T cells. Front Immunol (2014) 1.04
Enhanced Th17 differentiation and aggravated arthritis in IEX-1-deficient mice by mitochondrial reactive oxygen species-mediated signaling. J Immunol (2012) 1.04
Role of Th17 Cells in the Pathogenesis of Human IBD. ISRN Inflamm (2014) 1.04
Sox5 and c-Maf cooperatively induce Th17 cell differentiation via RORγt induction as downstream targets of Stat3. J Exp Med (2014) 1.03
Regulation of TH17 cell differentiation by innate immune signals. Cell Mol Immunol (2012) 1.03
Adventitial fibroblasts induce a distinct proinflammatory/profibrotic macrophage phenotype in pulmonary hypertension. J Immunol (2014) 1.03
FOXP3+ regulatory T cells and their functional regulation. Cell Mol Immunol (2015) 1.02
Regulatory T cells exhibit decreased proliferation but enhanced suppression after pulsing with sirolimus. Am J Transplant (2012) 1.01
Treg functional stability and its responsiveness to the microenvironment. Immunol Rev (2014) 1.01
Induced miR-99a expression represses Mtor cooperatively with miR-150 to promote regulatory T-cell differentiation. EMBO J (2015) 1.00
The mTOR pathway and integrating immune regulation. Immunology (2013) 0.99
Th17 cells have stem cell-like features and promote long-term immunity. Oncoimmunology (2012) 0.98
Regulatory T cells in radiotherapeutic responses. Front Oncol (2012) 0.98
Intratumor hypoxia promotes immune tolerance by inducing regulatory T cells via TGF-β1 in gastric cancer. PLoS One (2013) 0.97
Transcriptional and epigenetic regulation of T-helper lineage specification. Immunol Rev (2014) 0.97
Inactivation of the enzyme GSK3α by the kinase IKKi promotes AKT-mTOR signaling pathway that mediates interleukin-1-induced Th17 cell maintenance. Immunity (2012) 0.97
Recent advances in understanding the molecular mechanisms of the development and function of Th17 cells. Genes Cells (2013) 0.97
Murine lupus susceptibility locus Sle1c2 mediates CD4+ T cell activation and maps to estrogen-related receptor γ. J Immunol (2012) 0.96
Harnessing FOXP3+ regulatory T cells for transplantation tolerance. J Clin Invest (2014) 0.95
Foxp3 protein stability is regulated by cyclin-dependent kinase 2. J Biol Chem (2013) 0.95
Ways to enhance lymphocyte trafficking into tumors and fitness of tumor infiltrating lymphocytes. Front Oncol (2013) 0.95
IL-17 in the rheumatologist's line of sight. Biomed Res Int (2013) 0.95
Distinct metabolic programs in activated T cells: opportunities for selective immunomodulation. Immunol Rev (2012) 0.94
Transcriptional regulation by hypoxia inducible factors. Crit Rev Biochem Mol Biol (2013) 0.94
The role of inflammation in hypoxic pulmonary hypertension: from cellular mechanisms to clinical phenotypes. Am J Physiol Lung Cell Mol Physiol (2014) 0.94
Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature (2006) 46.36
The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell (2006) 33.94
TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity (2006) 29.29
Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med (2003) 26.05
Transforming growth factor-beta induces development of the T(H)17 lineage. Nature (2006) 25.91
IL-17 and Th17 Cells. Annu Rev Immunol (2009) 23.02
Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity (2005) 23.00
Regulatory T cells and immune tolerance. Cell (2008) 18.77
IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol (2007) 14.99
TGF-beta-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing RORgammat function. Nature (2008) 14.26
T helper 17 lineage differentiation is programmed by orphan nuclear receptors ROR alpha and ROR gamma. Immunity (2007) 13.29
Differentiation of effector CD4 T cell populations (*). Annu Rev Immunol (2010) 11.80
The lineage decisions of helper T cells. Nat Rev Immunol (2002) 10.61
STAT3 regulates cytokine-mediated generation of inflammatory helper T cells. J Biol Chem (2007) 10.41
Molecular antagonism and plasticity of regulatory and inflammatory T cell programs. Immunity (2008) 10.26
The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins. Nature (2008) 10.15
TH17 cells in development: an updated view of their molecular identity and genetic programming. Nat Rev Immunol (2008) 8.95
A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat Med (2009) 7.45
Role of conserved non-coding DNA elements in the Foxp3 gene in regulatory T-cell fate. Nature (2010) 6.87
The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment. Immunity (2009) 6.86
HIF1alpha-dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells. J Exp Med (2011) 5.99
The costimulatory molecule ICOS regulates the expression of c-Maf and IL-21 in the development of follicular T helper cells and TH-17 cells. Nat Immunol (2008) 5.92
Th17 and regulatory T cells in mediating and restraining inflammation. Cell (2010) 5.89
Either a Th17 or a Th1 effector response can drive autoimmunity: conditions of disease induction affect dominant effector category. J Exp Med (2008) 5.25
The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2. Nat Immunol (2011) 5.22
Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal. Nat Immunol (2009) 5.20
Digoxin and other cardiac glycosides inhibit HIF-1alpha synthesis and block tumor growth. Proc Natl Acad Sci U S A (2008) 4.79
An essential role for p300/CBP in the cellular response to hypoxia. Proc Natl Acad Sci U S A (1996) 4.57
Hypoxia-inducible factor 1 (HIF-1) pathway. Sci STKE (2007) 4.46
Cutting edge: An in vivo requirement for STAT3 signaling in TH17 development and TH17-dependent autoimmunity. J Immunol (2007) 4.29
Cutting Edge: IL-2 is essential for TGF-beta-mediated induction of Foxp3+ T regulatory cells. J Immunol (2007) 4.12
The AP-1 transcription factor Batf controls T(H)17 differentiation. Nature (2009) 3.75
Regulation of the p300 HAT domain via a novel activation loop. Nat Struct Mol Biol (2004) 3.70
Diverse targets of the transcription factor STAT3 contribute to T cell pathogenicity and homeostasis. Immunity (2010) 3.52
Interleukin-23 drives intestinal inflammation through direct activity on T cells. Immunity (2010) 3.51
Regulatory T cells reinforce intestinal homeostasis. Immunity (2009) 3.27
Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene (2005) 3.05
Eos mediates Foxp3-dependent gene silencing in CD4+ regulatory T cells. Science (2009) 2.76
Integration of calcineurin and MEF2 signals by the coactivator p300 during T-cell apoptosis. EMBO J (2000) 2.22
Measurement of absolute oxygen levels in cells and tissues using oxygen sensors and 2-nitroimidazole EF5. Methods Enzymol (2002) 1.94
Cutting edge: hypoxia-inducible factor 1alpha and its activation-inducible short isoform I.1 negatively regulate functions of CD4+ and CD8+ T lymphocytes. J Immunol (2006) 1.93
A role for the transcription factor Helios in human CD4(+)CD25(+) regulatory T cells. Mol Immunol (2010) 1.65
Emergence of the Th17 pathway and its role in host defense. Adv Immunol (2008) 1.65
Redox regulation of the hypoxia-inducible factor. Biol Chem (2006) 1.40
Effects of interleukin (IL)-17A and IL-17F in human rheumatoid arthritis synoviocytes. Ann Rheum Dis (2011) 1.40
mTOR: taking cues from the immune microenvironment. Immunology (2009) 1.38
Lymphocyte development: overview. Curr Opin Immunol (2008) 0.97
Calmodulin-dependent protein kinase IV regulates nuclear export of Cabin1 during T-cell activation. EMBO J (2005) 0.95
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24
c-Myc-regulated microRNAs modulate E2F1 expression. Nature (2005) 31.81
Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science (2002) 19.77
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol (2010) 17.13
Cancer regression in patients after transfer of genetically engineered lymphocytes. Science (2006) 16.96
Development of human protein reference database as an initial platform for approaching systems biology in humans. Genome Res (2003) 14.79
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med (2003) 14.59
c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature (2009) 13.28
HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab (2006) 13.22
Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med (2012) 13.12
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med (2015) 13.08
Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol (2005) 12.88
Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet (2007) 10.78
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A (2003) 10.71
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol (2014) 9.86
Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol (2005) 9.72
Otto Warburg's contributions to current concepts of cancer metabolism. Nat Rev Cancer (2011) 9.68
Genome-wide association study identifies a new breast cancer susceptibility locus at 6q25.1. Nat Genet (2009) 8.44
Mitochondrial autophagy is an HIF-1-dependent adaptive metabolic response to hypoxia. J Biol Chem (2008) 7.71
The Genomes of Oryza sativa: a history of duplications. PLoS Biol (2005) 7.67
A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat Med (2009) 7.45
Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol (2006) 7.40
Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1. Cell (2011) 7.33
Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol (2012) 7.26
Cancer's molecular sweet tooth and the Warburg effect. Cancer Res (2006) 7.24
Global histone modification patterns predict risk of prostate cancer recurrence. Nature (2005) 7.03
A highly annotated whole-genome sequence of a Korean individual. Nature (2009) 6.91
A draft sequence for the genome of the domesticated silkworm (Bombyx mori). Science (2004) 6.62
HIF-1 regulates cytochrome oxidase subunits to optimize efficiency of respiration in hypoxic cells. Cell (2007) 6.31
HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of C-MYC activity. Cancer Cell (2007) 6.06
Cancer immunotherapy comes of age. J Clin Oncol (2011) 5.87
Expression of programmed death 1 ligands by murine T cells and APC. J Immunol (2002) 5.78
Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1. Blood (2004) 5.71
Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer (2007) 5.65
Immortalization of human bronchial epithelial cells in the absence of viral oncoproteins. Cancer Res (2004) 5.57
Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol (2005) 5.36
Mechanisms of immune evasion by tumors. Adv Immunol (2006) 5.34
Global mapping of c-Myc binding sites and target gene networks in human B cells. Proc Natl Acad Sci U S A (2006) 5.27
IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med (2009) 5.05
Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. Cancer Cell (2010) 5.02
Myc stimulates nuclearly encoded mitochondrial genes and mitochondrial biogenesis. Mol Cell Biol (2005) 4.99
Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc Natl Acad Sci U S A (2010) 4.97
HIF-dependent antitumorigenic effect of antioxidants in vivo. Cancer Cell (2007) 4.81
Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cells. Cell Metab (2012) 4.80
Digoxin and other cardiac glycosides inhibit HIF-1alpha synthesis and block tumor growth. Proc Natl Acad Sci U S A (2008) 4.79
PTIP associates with MLL3- and MLL4-containing histone H3 lysine 4 methyltransferase complex. J Biol Chem (2007) 4.79
GeneWays: a system for extracting, analyzing, visualizing, and integrating molecular pathway data. J Biomed Inform (2004) 4.57
An integrated database of genes responsive to the Myc oncogenic transcription factor: identification of direct genomic targets. Genome Biol (2003) 4.49
Role of LAG-3 in regulatory T cells. Immunity (2004) 4.36
A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J Immunother (2002) 4.31
Cutting edge: An in vivo requirement for STAT3 signaling in TH17 development and TH17-dependent autoimmunity. J Immunol (2007) 4.29
Human-induced pluripotent stem cells from blood cells of healthy donors and patients with acquired blood disorders. Blood (2009) 4.22
Identification of JmjC domain-containing UTX and JMJD3 as histone H3 lysine 27 demethylases. Proc Natl Acad Sci U S A (2007) 4.20
Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. J Clin Oncol (2002) 4.15
Cord-blood transplants from unrelated donors in patients with Hurler's syndrome. N Engl J Med (2004) 4.15
Frontiers of biomedical text mining: current progress. Brief Bioinform (2007) 4.11
Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia. Nat Genet (2002) 4.06
Candidate exome capture identifies mutation of SDCCAG8 as the cause of a retinal-renal ciliopathy. Nat Genet (2010) 3.99
Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int J Radiat Biol (2006) 3.98
Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res (2011) 3.81
Lin-28B transactivation is necessary for Myc-mediated let-7 repression and proliferation. Proc Natl Acad Sci U S A (2009) 3.76
Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma. J Immunol (2005) 3.73
Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors. Cancer Cell (2009) 3.71
Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res (2012) 3.68
Hypoxia-inducible factor 1 and dysregulated c-Myc cooperatively induce vascular endothelial growth factor and metabolic switches hexokinase 2 and pyruvate dehydrogenase kinase 1. Mol Cell Biol (2007) 3.51
Interferon-producing killer dendritic cells provide a link between innate and adaptive immunity. Nat Med (2006) 3.49
Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma. Cancer (2003) 3.47
Lineage-specific gene duplication and loss in human and great ape evolution. PLoS Biol (2004) 3.45
Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol (2003) 3.38
Cell type-specific regulation of angiogenic growth factor gene expression and induction of angiogenesis in nonischemic tissue by a constitutively active form of hypoxia-inducible factor 1. Circ Res (2003) 3.34
Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother (2007) 3.32
Total synthesis of a functional designer eukaryotic chromosome. Science (2014) 3.31
Complete loss of ischaemic preconditioning-induced cardioprotection in mice with partial deficiency of HIF-1 alpha. Cardiovasc Res (2007) 3.31
Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. Cancer Res (2010) 3.30
Soy food intake and breast cancer survival. JAMA (2009) 3.16
Neither agouti-related protein nor neuropeptide Y is critically required for the regulation of energy homeostasis in mice. Mol Cell Biol (2002) 3.14
Heterozygous HIF-1alpha deficiency impairs carotid body-mediated systemic responses and reactive oxygen species generation in mice exposed to intermittent hypoxia. J Physiol (2006) 3.12
Major histocompatibility complex class II-restricted presentation of a cytosolic antigen by autophagy. Eur J Immunol (2003) 3.12
RACK1 competes with HSP90 for binding to HIF-1alpha and is required for O(2)-independent and HSP90 inhibitor-induced degradation of HIF-1alpha. Mol Cell (2007) 3.09
Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother (2010) 3.06
Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene (2005) 3.05
Hypoxia-inducible factor-1-dependent repression of E-cadherin in von Hippel-Lindau tumor suppressor-null renal cell carcinoma mediated by TCF3, ZFHX1A, and ZFHX1B. Cancer Res (2006) 3.05